- Open Access
Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice
© Pfeilschifter et al; licensee BioMed Central Ltd. 2011
- Received: 26 January 2011
- Accepted: 9 March 2011
- Published: 9 March 2011
FTY720, an immunomodulator derived from a fungal metabolite which reduces circulating lymphocyte counts by increasing the homing of lymphocytes to the lymph nodes has recently gained interest in stroke research. The aim of this study was to evaluate the protective efficacy of FTY720 in cerebral ischemia in two different application paradigms and to gather first data on the effect of FTY720 on the rate of spontaneous bacterial infections in experimental stroke.
Middle cerebral artery occlusion (MCAO) in C57BL/6 mice (strain J, groups of 10 animals) was performed with two different durations of ischemia (90 min and 3 h) and FTY720 was applied 2 h after vessel occlusion to study the impact of reperfusion on the protective potency of FTY720. Lesion size was determined by TTC staining. Mice treated with FTY720 or vehicle were sacrificed 48 h after 90 min MCAO to determine the bacterial burden in lung and blood.
FTY720 1 mg/kg significantly reduced ischemic lesion size when administered 2 h after the onset of MCAO for 3 h (45.4 ± 22.7 mm3 vs. 84.7 ± 23.6 mm3 in control mice, p = 0.001) and also when administered after reperfusion, 2 h after the onset of MCAO for 90 min (31.1 ± 28.49 mm3 vs. 69.6 ± 27.2 mm3 in control mice, p = 0.013). Bacterial burden of lung homogenates 48 h after stroke did not increase in the group treated with the immunomodulator FTY720 while there was no spontaneous bacteremia 48 h after MCAO in treated and untreated animals.
Our results corroborate the experimental evidence of the protective effect of FTY720 seen in different rodent stroke models. Interestingly, we found no increase in bacterial lung infections even though FTY720 strongly reduces the number of circulating leukocytes.
- Cerebral Ischemia
- Middle Cerebral Artery Occlusion
- Lung Homogenate
- Experimental Stroke
Despite decades of basic and translational research, there is still no pharmaceutical stroke treatment besides thrombolysis which has been proven to be effective in humans . To promote the transition of scientific evidence from animal studies on experimental stroke, the Stroke Therapy Academic Industry Roundtable (STAIR) has formulated a set of criteria for the conduct, reporting, and analysis of animal data which include the points that drug candidates should be tried by different research teams, in different stroke models, in different animal species, and at different time points . One drug, which has recently gained a lot of interest and already fulfils some of these criteria on the basis of the current experimental evidence is the sphingosine 1-phosphate (S1P) analogue and immunomodulator FTY720 (fingolimod).
FTY720 is phosphorylated to yield the biologically active substance FTY720-phosphate by the ubiquitously available sphingosine kinase-2 and to a lesser extent by sphingosine kinase-1 . FTY720-phosphate can activate four of the five G protein-coupled S1P receptors known so far . It leads to a downregulation of autoimmune-inflammatory responses by inducing the internalization of the S1P1 receptor of lymphocytes and thus inhibits the lymphocyte egress from the lymph node into the systemic circulation , while the functional responses of the lymphocytes remain relatively unaltered .
FTY720 has been shown to reduce lesion size and improve neurological outcome after experimental stroke in mice [6, 7] and rats [7, 8] with a therapeutic time window of up to four hours after the induction of ischemia . It has been shown to reduce brain damage after stroke in models of transient [6–8] and permanent  middle cerebral artery occlusion (MCAO) by reducing the infiltration of neutrophils into the ischemic lesion , attenuating the activation of microglia/macrophages , reducing hallmarks of apoptotic cell death within the lesion and activating survival pathways via Akt and ERK phosphorylation  in the ischemic brain. The protective effect on lesion size was still present at 72 h after MCAO  and FTY720-treated mice performed better than controls in a behavioural test performed 15 days after experimental stroke .
It is well known that cerebral ischemia has a profound effect on the immune system, leading to an immunosuppression with reduced leukocyte counts and reactivity as well as an atrophy of secondary lympoid tissues after stroke . Stroke patients are prone to infections, predominantly chest and urinary tract infections  and pneumonia is the complication with the highest attributable risk of death in the acute phase of stroke . In the MCAO model of cerebral ischemia, mice after stroke showed higher rates of spontaneous bacterial infections than control animals  and were more susceptible to infection after nasal inoculation of S. pneumoniae . In this context, it is of great interest whether FTY720 as an immunomodulatory substance which reduces the number of circulating leukocytes, especially T cells, is associated with a higher rate of infectious complications. The aim of this study was to evaluate the efficacy of FTY720 in two different application paradigms before and after vessel recanalization in large territorial infarctions and to gather first data on the effect of FTY720 on the rate of spontaneous bacterial infections in experimental stroke.
Animals and sample size calculation
Male C57BL/6 mice (10 weeks old, strain J) were used in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996). The experiments were approved by the local governmental authorities (Regierungspraesidium Darmstadt, Germany, approval number F143/34). In pilot experiments of the two application paradigms for FTY720 tested in this study, we found a reduction in lesion size of approximately 50% with a standard deviation of 0.33 to 0.5 of the lesion size leading to an effect size (Cohen's d) of 1.697 . To detect this effect size with an alpha level of 0.05 and a statistical power of 0.9, nine animals per group were needed. 10 animals per group were randomized to receive either FTY720 or vehicle.
Middle cerebral artery occlusion
The operator was blinded to the treatment status of the animals. Transient MCAO was performed as described previously  in groups of 10 vs. 10 animals per application paradigm. Mice were anaesthetized with 1.5% isoflurane (Forene; Abbott, Wiesbaden, Germany) and 0.1 mg/kg buprenorphine (Temgesic; Essex Pharma, Munich, Germany) under spontaneous respiration. Focal cerebral ischemia was induced by introducing a silicone-coated 7-0 monofilament until it occluded the ostium of the right MCA. Regional cerebral blood flow was monitored by laser Doppler flowmetry (PF5010, Perimed, Järfälla, Sweden) to confirm vessel occlusion. The filament was withdrawn after the indicated time points, i.e. 3 h or 90 min, to allow reperfusion of the ischemic hemisphere. Animals were sacrificed at 24 h, 36 h or 48 h after assessment of their global neurological functions with a 5-point neuroscore (0 = no deficit, 1 = failure to extend left paw, 2 = circling to the left, 3 = falling to the left, 4 = unable to walk spontaneously, 5 = death). All animals that showed a drop of the Doppler flow below 40% of the initial value and a neurological deficit (neuroscore ≥ 1) were included in the analysis.
Dosing and administration of FTY720
FTY720 (Cayman Chemicals Europe, Tallinn, Estonia) was dissolved in 0.9% NaCl at a final concentration of 125 μg/ml yielding a clear liquid and 200 - 250 μl were injected intraperitoneally 2 h after the onset of cerebral ischemia. Control animals received the corresponding volume of 0.9% NaCl i.p. Syringes were prepared by an allocator and administered by the operator in a blinded fashion.
Assessment of ischemic lesion volume
Twenty-four hours after the onset of ischemia, brains were removed and cut into sections of 1 mm thickness using a mouse brain matrix (RBM 2000C; ASI Instruments, Warren, Mich; USA). The brain sections were stained in 2% (w/v) 2,3,5-triphenyltetrazolium chloride (TTC, Merck, Darmstadt, Germany) in phosphate buffer at 37°C for 10 minutes. Brain slices were digitized and infarct volumes were measured by an observer who was blinded to the treatment conditions with the National Institutes of Health Image J software analysing four slices of identical positions adjacent to the bregma. The correction for edema was established by multiplying the infarct section volume by the ratio of the contralateral to the ischemic hemisphere section volume.
Mice were subjected to 90 min MCAO and substance application at the onset of reperfusion. Thereafter, mice were returned to their cages for 24 h, 36 h and 48 h to observe whether they developed spontaneous bacterial infections. Only mice that showed a neurological deficit after 24 h were used for further analyses. 24 h, 36 h and 48 h after the induction of cerebral ischemia, the anesthetized mice were washed in 70% alcohol under sterile conditions. Lungs were removed and homogenized in sterile phosphate-buffered solution. For the determination of the bacterial load, Blood was drawn from the heart into an EDTA collection tube and 100 μl were serially diluted and plated onto blood and chocolate agar for anaerobic and aerobic incubation, respectively. 100 μl of lung homogenate were serially diluted and plated onto appropriate agar as described above. Colonies were counted after incubation for 48 h at 37°C. Lung infection was defined as any bacterial growth from the sterilely collected lung samples. Status of lung infection was categorized into four groups (no infection, <5.000 CFU/ml, >50.000 CFU/ml and death). Accordingly, these groups were further dichotomized into "moderate or no infection" and "severe infection or death".
Graph Pad Prism 4 (Graph Pad Software Inc., La Jolla, CA, USA) was used for statistical analysis. Results are given as mean ± SD and graphically presented as a box and whiskers plot depicting the mean, extreme values and the 25 - 75 interquartile range. Statistical significance was assessed with an unpaired, two-tailed student's t-test and a Mann-Whitney-Test where indicated. Statistical significance between the dichotomized infection rates in FTY- and vehicle-treated animals was tested with a two-sided chi-square test.
FTY720 significantly reduces lesion size in large territorial infarctions
FTY720 is also protective when administered after reperfusion
FTY720 does not increase the rate of bacterial infections at48 h after MCAO
Pulmonary infections 48 h after 90 min MCAO
Severe infection or death
Moderate or no infection
FTY720 1 mg/kg
Contingency table showing the number of mice in each group after the degree of infection was dichotomized into "moderate or nor infection" and "severe infection or death". Statistical significance was assayed with a Chi-square test, p = 0.033.
Adding to the considerable body of experimental evidence on the protective effect of FTY720 in stroke [6–8], our experiments show that FTY720 is also protective in large hemispheric infarctions within a therapeutic time window that is achievable in patient care. Even if administered after the critical time point of reperfusion, it still leads to a significant reduction in ischemic lesion size.
After two successful phase III trials [14, 15] FTY720 has been approved as the first orally available drug to treat relapsing-remitting multiple sclerosis by the FDA in 2010. In over 1200 patients, FTY720 was generally well tolerated and did not lead to a significantly elevated rate of infections, but two cases of severe viral infections occurred in the verum groups. The highest dose in the aforementioned trials was 1.25 mg (approx. 0.02 mg/kg) administered as a chronic daily dose, which is fiftyfold lower than the dose of 1 mg/kg required for a protective effect in experimental stroke in mice . The highest dose reported in humans so far was 5 mg administered on a daily basis  and dosing was limited by the S1P receptor-mediated bradycardia which occurs within hours after FTY720 intake.
FTY720 leads to a reduction of circulating immune cells, especially T cells, as we have shown previously . At 1 mg/kg, the number of circulating neutrophils is also reduced [, and Pfeilschifter W. unpublished observations]. Especially in consideration of the well-described phenomenon of stroke-induced immunosuppression (cerebral injury induced immune deficiency syndrome, CIDS) , it is important to take account of the influence of FTY720-treatment on the rate of stroke-associated infections because they constitute an important factor that modulates the outcome of stroke patients . We observed varying degrees of bacterial colonization in the lungs of mice 48 h after stroke and only very few lung homogenate samples remained sterile during incubation. This is in accordance with an earlier study , corroborating the hypothesis that mice after stroke are prone to bacterial lung infections. However, in contrast to the aforementioned study, which documented the first cases of bacterial lung infection after 12 h with a constant rise of the incidence of infection and bacterial load over the following 72 h as well as blood stream infections beginning at 24 h after stroke, we neither found bacteremia at all after 48 h nor lung infections at the 24 h and 36 h time points. There are several possible explanations for this divergence. Since both experiments detected spontaneous bacterial infections, the local spectrum of bacteria in the respective animal care facilities might be one determinant. Since the degree of CIDS is critically determined by the size of the brain lesion both in humans  and in mice , differences in ischemic lesion size might also explain differences in the susceptibility to bacterial infections. An analysis of the results of our microbiological examination dichotomized in moderate and severe pulmonary infections even showed a significantly lower rate of severe infections in FTY720-treated animals compared to controls. One possible explanation is that given the immunosuppressive effect of acute brain lesions, the reduction of lesion size achieved by FTY720 might outweigh its immunomodulatory effect. Nonetheless, given the small number of animals, these results have to be interpreted with utmost care.
While corroborating the protective effect of FTY720 in stroke in various rodent models and modes of application, our data also suggest that FTY720 does not further aggravate stroke-induced immune depression to a clinically relevant degree as evaluated microbiologically.
Acknowledgements and Funding
W. Pfeilschifter was supported by a stipend of the Medical Faculty of the Goethe-University (Patenschaftsmodell).
- O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW: 1,026 experimental treatments in acute stroke. Ann Neurol 2006, 59: 467–477.PubMedView ArticleGoogle Scholar
- Dirnagl U: Bench to bedside. The quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006, 26: 1465–1478. 10.1038/sj.jcbfm.9600298PubMedView ArticleGoogle Scholar
- Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003, 278: 47408–47415. 10.1074/jbc.M307687200PubMedView ArticleGoogle Scholar
- Brinkmann V: FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009, 158: 1173–1182. 10.1111/j.1476-5381.2009.00451.xPubMed CentralPubMedView ArticleGoogle Scholar
- Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998, 160: 5493–4399.PubMedGoogle Scholar
- Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel MA, Kahles T, Neumann-Haefelin T, Rami A, Huwiler A, Pfeilschifter J: The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun 2009, 389: 251–256. 10.1016/j.bbrc.2009.08.142PubMedView ArticleGoogle Scholar
- Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, Guo S, Qin T, Alsharif N, Brinkmann V, Liao JK, Lo EH, Waeber C: Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 2011, 69: 119–29. 10.1002/ana.22186PubMed CentralPubMedView ArticleGoogle Scholar
- Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang J: Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 2010, 41: 368–374. 10.1161/STROKEAHA.109.568899PubMed CentralPubMedView ArticleGoogle Scholar
- Offner H, Vandenbark AA, Hurn PD: Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience 2009, 158: 1098–1111. 10.1016/j.neuroscience.2008.05.033PubMed CentralPubMedView ArticleGoogle Scholar
- Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, Dick F, Taylor GS, Murray G: Medical complications after stroke: a multicenter study. Stroke 2003, 31: 1223–1229.View ArticleGoogle Scholar
- Heuschmann PU, Kolominsky-Rabas PL, Misselwitz B, Hermanek P, Leffmann C, Janzen RW, Rother J, Buecker-Nott HJ, Berger K, German Stroke Registers Study Group: Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group. Arch Intern Med 2004, 164: 1761–1768. 10.1001/archinte.164.16.1761PubMedView ArticleGoogle Scholar
- Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, Ruscher K, Victorov IV, Priller J, Dirnagl U, Volk HD, Meisel A: Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003, 198: 725–236. 10.1084/jem.20021098PubMed CentralPubMedView ArticleGoogle Scholar
- A priori sample size calculation [http://www.danielsoper.com/statcalc/calc47.aspx]
- Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362: 387–401. 10.1056/NEJMoa0909494PubMedView ArticleGoogle Scholar
- Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group: Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362: 402–15. 10.1056/NEJMoa0907839PubMedView ArticleGoogle Scholar
- Dragun D, Fritsche L, Boehler T, Peters H, Budde K, Neumayer HH: FTY720: early clinical experience. Transplant Proc 2004,36(Suppl 2):544S-548S. 10.1016/j.transproceed.2003.12.048PubMedView ArticleGoogle Scholar
- Downes S, Chen YJ, Kyles A, Gregory C: Oral pharmacokinetic and pharmacodynamic effects of FTY720 in cats. J Vet Pharmacol Ther 2007, 30: 55–61. 10.1111/j.1365-2885.2007.00815.xPubMedView ArticleGoogle Scholar
- Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U: Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005, 6: 775–86. 10.1038/nrn1765PubMedView ArticleGoogle Scholar
- Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, Auffarth G, Liesz A, Veltkamp R: Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 2009, 40: 3226–32. 10.1161/STROKEAHA.109.557967PubMedView ArticleGoogle Scholar
- Illanes S, Liesz A, Sun L, Dalpke A, Zorn M, Veltkamp R: Hematoma size is a major modulator of the cellular immune system after experimental intracerebral hemorrhage. Neurosci Lett 2011, 490: 170–4. 10.1016/j.neulet.2010.11.065PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.